The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine
about
A glial variant of the vesicular monoamine transporter is required to store histamine in the Drosophila visual systemVMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuseVesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistryTrafficking of vesicular neurotransmitter transportersThe role of mechanical forces and adenosine in the regulation of intestinal enterochromaffin cell serotonin secretionVariations in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) are associated with bipolar i disorderRauwolfia in the Treatment of HypertensionCatecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disordersHypotonic activation of the myo-inositol transporter SLC5A3 in HEK293 cells probed by cell volumetry, confocal and super-resolution microscopySaccharomyces cerevisiae Aqr1 is an internal-membrane transporter involved in excretion of amino acidsRole of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazineVesicular monoamine transporter 1 mediates dopamine secretion in rat proximal tubular cellsGenetic variations in the serotonergic system contribute to amygdala volume in humansNicotine Activity on Dopaminergic NeuronsThe Drosophila vesicular monoamine transporter reduces pesticide-induced loss of dopaminergic neurons.The Concise Guide to PHARMACOLOGY 2013/14: transporters.A tyrosine-based motif localizes a Drosophila vesicular transporter to synaptic vesicles in vivo.Immunocytochemical identification of proteins involved in dopamine release from the somatodendritic compartment of nigral dopaminergic neurons.Protonophore properties of hyperforin are essential for its pharmacological activity.Dopamine D1, D2, D3 receptors, vesicular monoamine transporter type-2 (VMAT2) and dopamine transporter (DAT) densities in aged human brain.VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease.Catecholamines 101The stimulatory adenosine receptor ADORA2B regulates serotonin (5-HT) synthesis and release in oxygen-depleted EC cells in inflammatory bowel diseaseThe evolution of dopamine systems in chordates.VMAT1 deletion causes neuronal loss in the hippocampus and neurocognitive deficits in spatial discriminationAction potentials and amphetamine release antipsychotic drug from dopamine neuron synaptic VMAT vesicles.Molecular basis of essential amino acid transport from studies of insect nutrient amino acid transporters of the SLC6 family (NAT-SLC6)Characterization of human SLC4A10 as an electroneutral Na/HCO3 cotransporter (NBCn2) with Cl- self-exchange activity.Identification of molecular hinge points mediating alternating access in the vesicular monoamine transporter VMAT2.Coexpression of cholinergic and noradrenergic phenotypes in human and nonhuman autonomic nervous system.Drosophila vesicular monoamine transporter mutants can adapt to reduced or eliminated vesicular stores of dopamine and serotoninSweat gland innervation is pioneered by sympathetic neurons expressing a cholinergic/noradrenergic co-phenotype in the mouseCharacterisation of Weibel-Palade body fusion by amperometry in endothelial cells reveals fusion pore dynamics and the effect of cholesterol on exocytosis.Localization and expression of VMAT2 aross mammalian species: a translational guide for its visualization and targeting in health and disease.Species-specific vesicular monoamine transporter 2 (VMAT2) expression in mammalian pancreatic beta cells: implications for optimising radioligand-based human beta cell mass (BCM) imaging in animal models.Targets and probes for non-invasive imaging of β-cells.Hijacking solute carriers for proton-coupled drug transport.Are vesicular neurotransmitter transporters potential treatment targets for temporal lobe epilepsy?PET radioligands for the vesicular transporters for monoamines and acetylcholine.Exocytosis and synaptic vesicle function.
P2860
Q21092469-7D110DF5-46D8-4967-84B4-A65490F7A798Q22242306-05C3CC85-6399-4BB2-B6FE-4D0CDAADC461Q24601233-69D12585-53E6-41F8-8975-5AF4472ED075Q24619054-6A98E406-0077-4CB5-83CF-87E36792A360Q24629948-A5B54351-CCF5-40CB-B7D7-1D6961AAA366Q24645725-FF3E5EC5-0FD8-41D2-AEE7-1B1503096A78Q26771935-84B39C49-7663-406F-92BC-4329F0EF1D32Q26826093-28754326-9E4F-4F30-8A5F-0DFBA5E1EDE8Q27311615-86D0C669-A1CE-4352-B3FF-36B54F57DE43Q27931298-509BE9E6-7106-4F6A-9A0E-7D650D0F1E7EQ28565154-3EB05671-5CE1-4BB1-BB1B-4C9D4AEA24B1Q28579269-5BF70E45-5680-4010-A253-99C07E410AD3Q28606617-6AA2A89A-E173-4892-A773-41EE4BB01698Q29883383-5112B7B4-BB1F-426C-BF2F-6FC035B258A7Q30430534-6D291AA0-EE0E-4F62-A328-A0A0B20B3400Q30486743-368D88DA-8B1A-4B0F-8451-6A36B4FDB440Q33747909-844770CA-3356-4DBB-A180-BE9AA7544A02Q33888274-48FE1938-04E0-4E72-B9C9-4D6E7FF5DF47Q34453993-73F8308C-28B9-48B8-97E3-EA04FAD924EDQ34490087-4086E913-ED2B-48A0-86C2-27F12369C729Q34595165-39709C8C-1E6D-4DB9-AA9D-6165CB76573CQ34611815-2987EE4C-5B22-45D1-8A40-870353884F99Q34701850-70A1D72E-4D3C-49E0-BA12-FB0B460BA7CCQ34758213-CA5A4C12-D54A-4C3C-B510-CE4DD59B19B8Q35191319-7F20A646-CE30-4549-85D9-1BD66184F9DCQ35961288-03ABCD59-7D05-481D-B6ED-549E719631BDQ36096856-B8BD9850-4DD4-4501-BC35-A9A56A65265FQ36741568-943AF9BE-492B-4B58-A128-66953B604738Q36762583-1CF3855A-07C1-4F96-96B2-F63F7C876C57Q36996150-4529FA63-FE29-49F4-B7E9-27E52C05BC2FQ37102620-234D255A-CBA1-4547-9D4B-42F2C86EFE88Q37209754-93C56FCB-24BD-47E8-B5C8-735AE0900181Q37349128-CDEE49B5-7671-40E5-A765-80DEE27B82F3Q37591449-D570A0C4-9952-485F-9388-FD07F09F5559Q37640085-63B6CC66-A69C-42D5-AC03-965332B360F1Q37662672-0CF1CAE3-6FF9-4817-9783-886FB2C05344Q37824123-5AB2CE6A-A511-4584-95FB-1BA171AEC3D0Q38134724-6EEB41BF-357A-4B58-9A32-92554BBDAE61Q38166971-DA4D17FD-D441-472F-B091-4D10F659753DQ38201382-03CBE46C-22BE-4289-B0AF-00E703F39117
P2860
The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
The vesicular amine transporte ...... f monoamines and acetylcholine
@ast
The vesicular amine transporte ...... f monoamines and acetylcholine
@en
The vesicular amine transporte ...... f monoamines and acetylcholine
@en-gb
The vesicular amine transporte ...... f monoamines and acetylcholine
@nl
type
label
The vesicular amine transporte ...... f monoamines and acetylcholine
@ast
The vesicular amine transporte ...... f monoamines and acetylcholine
@en
The vesicular amine transporte ...... f monoamines and acetylcholine
@en-gb
The vesicular amine transporte ...... f monoamines and acetylcholine
@nl
prefLabel
The vesicular amine transporte ...... f monoamines and acetylcholine
@ast
The vesicular amine transporte ...... f monoamines and acetylcholine
@en
The vesicular amine transporte ...... f monoamines and acetylcholine
@en-gb
The vesicular amine transporte ...... f monoamines and acetylcholine
@nl
P2093
P1433
P1476
The vesicular amine transporte ...... f monoamines and acetylcholine
@en
P2093
Burkhard Schütz
Eberhard Weihe
Martin K-H Schäfer
P2888
P304
P356
10.1007/S00424-003-1100-5
P407
P50
P577
2003-06-24T00:00:00Z
P5875
P6179
1028397466